NICE gives final recomendation to Gazyvaro (obinutuzumab) for CLL- Genentech+ Roche
NICE (The National Institute for Health and Care Excellence) now recommends Gazyvaro (Gazyva in the US) (obinutuzumab) for chronic lymphocytic leukemia (CLL) for previously untreated patients and with co existing medical conditions which are unsuitable for full dose fludarabine based therapy and only if bendamustine therapy is also not suitable.
Comment;.Gazyvaro is the intended successor to Rituxan/MabThera (rituximab)and will eventually compete with rituximab biosmilars when they are introduced in 2017.The NICE decision reverses an earlier decision and came about assisted by revised cost effectiveness data, a discount and the introduction of a patient access scheme .
Related news and insights
Genentech/Roche announced that the FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with wet, or neovascular, age-related macular degeneration (AMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections.
Oncopeptides announced that the company has decided to withdraw Pepaxto (INN melphalan flufenamide) from the market in the US, following the phase III OCEAN study, which showed an overall survival in the ITT population with a HR of 1.104. The decision has been made after interactions and dialogue with the FDA. Pepaxto was granted accelerated approval on February 26th 2021.
Johnson & Johnson announced the FDA has issued Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following primary vaccination with single-shot Johnson & Johnson COVID-19 vaccine; and for eligible individuals who received a different authorized or approved COVID-19 vaccine.